RNS Number:0749X
Talisman Metals PLC
30 September 2026

Talisman Metals PLC
("Talisman" or the "Company")
Interim Results for the six months ended 30 June 2026
Talisman Metals PLC (“Talisman” or the “Company”) announces its interim financial statements and report covering the six‐months ended 30 June 2026.
A copy of the interim results is available at the Company’s website, https://talismanmetalsplc.com/investors/reports and extracts are included at the end of this announcement.
CEO Statement
Today we published Talisman's financial statements covering the six‐month period to the end of June 2026, which are also posted on our website. On 27 January 2026 the Company’s shareholders approved a transaction to acquire 100% of Tadeen International Limited ("Tadeen"), a UK‐registered company, which indirectly owns 100% of a portfolio of mineral exploration licenses in Morocco prospective for copper and silver (the “Transaction”). The Transaction set Talisman on a new course of development with a new team and focus. On 16 February 2026 the Company announced a binding agreement to acquire the Tirzzit Copper Project in Morocco from Aya Gold and Silver, Inc. (which is still in the process of regulatory transfer and management anticipates will be complete later this year). Subsequent to the reporting period end, on 20 August 2026 the Company completed a share placement of £501,800 in gross proceeds through the issue of 7,168,570 new ordinary shares. Throughout the entire reporting period and subsequently, the Company performed ongoing exploration work at both the Fougnar and Tirzzit Projects.
As at 30 June 2026, the Company had cash and cash equivalents amounting to €1.417 million (US$ 1.615 million) and management continues to carefully manage Talisman’s financial resources. The Company has no long-term debt nor any contingent future payments relating to its assets and projects. The costs incurred during the reporting period relate to the costs of closing the Transaction, as well as exploration activities and administration costs. I note that under IFRS accounting rules, and the financial nature of the Transaction, our Interim Results have not recognised any goodwill on the acquisition of our Moroccan projects as a non-current asset and all subsequent exploration expenditure has been expensed to the Income Statement. However, as we advance our Moroccan projects, the accounting treatment of this activity will be kept under review and may change.
I would like to thank the management team of the Company, our partners and contractors, and the Board of Directors for their support.
Tim McCutcheon – CEO and Director
End
For further information:
Talisman Metals PLC
Tim McCutcheon (Chief Executive Officer and Director)
Tel +353 (0) 1 525 6710
contactus@talismanmetalsplc.com
Beaumont Cornish Limited (Nominated Adviser)
James Biddle / Roland Cornish
Tel: +44 (0) 207 628 3396
CMC Markets UK Plc (Broker)
Thomas Smith / Thomas Curran
Tel: +44 (0) 20 3003 8255
BlytheRay (Financial PR)
Megan Ray / Said Izagaren
Tel: +44 (0) 20 7138 3204
Nominated Adviser Statement
Beaumont Cornish Limited ("Beaumont Cornish"), is the Company's Nominated Adviser and is authorised and regulated in the United Kingdom by the Financial Conduct Authority. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other person for providing the protections afforded to customers of Beaumont Cornish nor for advising them in relation to the transaction and arrangements described in the announcement or any matter referred to in it. Half Year Report
Distribution
This announcement has been notified via a Regulatory Information Service and it is not authorised for distribution into North America or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of that jurisdiction.
Half Year Report
|
Talisman Metals PLC | ||||||||
|
Interim results for the six months ended 30 June 2026 | ||||||||
|
|
|
|
|
|
|
|
|
|
|
CONDENSED CONSOLIDATED INCOME STATEMENT |
|
Unaudited |
|
Unaudited |
|
Unaudited |
|
Unaudited |
|
|
|
6 Months ended |
|
6 Months ended |
|
6 Months ended |
|
6 Months ended |
|
|
|
30/06/2026 |
|
30/06/2025 |
|
30/06/2026 |
|
30/06/2025 |
|
|
|
€'000 |
|
€'000 |
|
US $'000 |
|
US $'000 |
|
Continuing Operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exploration costs written off |
|
- |
|
- |
|
- |
|
- |
|
Gross loss |
|
- |
|
- |
|
- |
|
- |
|
|
|
|
|
|
|
|
|
|
|
Administration expenses |
|
(856) |
|
(632) |
|
(994) |
|
(729) |
|
Share option expense |
|
(8) |
|
0 |
|
(9) |
|
0 |
|
Other gains / losses |
|
(335) |
|
(531) |
|
(389) |
|
(612) |
|
Operating loss |
|
(1,199) |
|
(1,163) |
|
(1,392) |
|
(1,341) |
|
|
|
|
|
|
|
|
|
|
|
Finance costs |
|
(4) |
|
(3) |
|
(5) |
|
(3) |
|
Finance income |
|
- |
|
- |
|
- |
|
- |
|
Loss for the period before tax |
|
(1,203) |
|
(1,166) |
|
(1,397) |
|
(1,343) |
|
|
|
|
|
|
|
|
|
|
|
Income tax |
|
- |
|
- |
|
- |
|
- |
|
|
|
|
|
|
|
|
|
|
|
Loss for the period from continuing operations |
|
(1,203) |
|
(1,166) |
|
(1,397) |
|
(1,343) |
|
|
|
|
|
|
|
|
|
|
|
Discontinued operations |
|
- |
|
401 |
|
- |
|
464 |
|
|
|
|
|
|
|
|
|
|
|
Loss from discontinued operations net of tax |
|
- |
|
401 |
|
- |
|
464 |
|
|
|
|
|
|
|
|
|
|
|
Loss for the period |
|
(1,203) |
|
(765) |
|
(1,397) |
|
(879) |
|
|
|
|
|
|
|
|
|
|
|
Loss for the period attributable to: |
|
|
|
|
|
|
|
|
|
Owners of the parent |
|
(1,203) |
|
(765) |
|
(1,397) |
|
(879) |
|
|
|
(1,203) |
|
(765) |
|
(1,397) |
|
(879) |
|
|
|
|
|
|
|
|
|
|
|
Earning / (Loss) per share |
|
|
|
|
|
|
|
|
|
Basic loss per share from continuing operations |
|
(6.11) |
|
(1.32) |
|
(7.10) |
|
(1.54) |
|
Basic earnings per share from discontinued operations |
|
- |
|
0.45 |
|
- |
|
0.52 |
|
Fully diluted loss per share from continuing operations |
|
(6.11) |
|
(1.32) |
|
(7.10) |
|
(1.54) |
|
Fully diluted earnings per share from discontinued operations |
|
- |
|
0.45 |
|
- |
|
0.52 |
|
|
|
|
|
|
|
|
|
|
|
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE (LOSS)/INCOME |
|
|
|
|
|
| ||
|
|
|
Unaudited |
|
Unaudited |
|
Unaudited |
|
Unaudited |
|
|
|
6 Months ended |
|
6 Months ended |
|
6 Months ended |
|
6 Months ended |
|
|
|
30/06/2026 |
|
30/06/2025 |
|
30/06/2026 |
|
30/06/2025 |
|
|
|
€'000 |
|
€'000 |
|
US $'000 |
|
US $'000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss for the period |
|
(1,203) |
|
(765) |
|
(1,397) |
|
(879) |
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income/(expense): |
|
|
|
|
|
|
|
|
|
Items that may not be reclassified subsequently to profit or loss |
|
|
|
|
|
|
|
|
|
Fair value movement on equity securities designated as at FVOCI |
|
- |
|
- |
|
- |
|
- |
|
Exchange movement on equity securities designated as at FVOCI |
|
- |
|
- |
|
- |
|
- |
|
Items that may be reclassified subsequently to profit or loss |
|
|
|
|
|
|
|
|
|
Foreign exchange gain/(loss) arising from translation of financial statements of a foreign operation |
|
(1,274) |
|
(31) |
|
(1,531) |
|
216 |
|
Total comprehensive loss for the period |
|
(2,477) |
|
(796) |
|
(2,928) |
|
(663) |
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive loss for the period attributable to: |
|
|
|
|
|
|
|
|
|
Owners of the parent |
|
(2,477) |
|
(796) |
|
(2,928) |
|
(663) |
|
|
|
(2,477) |
|
(796) |
|
(2,928) |
|
(663) |
|
|
|
|
|
|
|
|
|
|
There is no income tax impact in respect of components recognised within the consolidated statement of comprehensive income.
|
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share capital |
Share Premium |
Capital Contribution |
Treasury Shares |
Share based payment reserve |
Other reserves |
Foreign Currency translation reserve |
Retained earnings |
Total (attributable to owners of the parent) |
|
Unaudited |
|
|
€'000 |
€'000 |
€'000 |
€'000 |
€'000 |
€'000 |
€'000 |
€'000 |
€'000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1 January 2026 |
|
|
11,057 |
0 |
13,550 |
0 |
46 |
1,288 |
5,591 |
(30,752) |
780 |
|
Share issue |
|
|
|
|
|
|
|
|
|
|
|
|
Share issue to purchase subsidiary |
|
|
694 |
2,155 |
|
|
|
|
|
|
2,849 |
|
|
|
|
694 |
2,155 |
- |
- |
- |
- |
- |
- |
2,849 |
|
Comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
Loss for the period |
|
|
- |
- |
- |
- |
|
- |
- |
(1,203) |
(1,203) |
|
Transfer to Retained Earnings following expiration of options |
|
|
|
|
|
|
|
|
|
46 |
46 |
|
|
|
|
|
|
|
|
|
|
|
(1,157) |
(1,157) |
|
Other comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange gain arising from translation of financial statements of a foreign operation |
|
|
- |
- |
- |
- |
- |
- |
(1,274) |
- |
(1,274) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive loss for the period |
|
|
- |
- |
- |
- |
- |
- |
(1,274) |
- |
(1,274) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Transactions with owners of the Company |
|
|
|
|
|
|
|
|
|
|
|
|
Options expired |
|
|
|
|
|
|
(46) |
|
|
|
(46) |
|
Share based payment movements |
|
|
- |
- |
- |
- |
42 |
- |
- |
- |
42 |
|
Total Transactions with the owners of the Company |
|
|
- |
- |
- |
- |
(4) |
- |
- |
- |
(4) |
|
Changes in ownership interest |
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of the remaining interest in a subsidiary |
|
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at 30 June 2026 |
|
|
11,751 |
2,155 |
13,550 |
0 |
42 |
1,288 |
4,317 |
(31,909) |
1,194 |
|
|
|
|
Share capital |
Share Premium |
Capital Contribution |
Treasury Shares |
Share based payment reserve |
Other reserves |
Foreign Currency translation reserve |
Retained earnings |
Total (attributable to owners of the parent) |
|
Unaudited |
|
|
€'000 |
€'000 |
€'000 |
€'000 |
€'000 |
€'000 |
€'000 |
€'000 |
€'000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1 January 2025 |
|
|
11,057 |
- |
- |
- |
46 |
1,288 |
5,468 |
(15,799) |
2,060 |
|
Comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
Loss for the period |
|
|
- |
- |
- |
- |
- |
- |
- |
(765) |
(765) |
|
Other comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
Movement on equity securities designated as at FVOCI |
|
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
|
Exchange movement on equity securities designated as at FVOCI |
|
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
|
Foreign exchange gain arising from translation of financial statements of a foreign operation |
|
|
- |
- |
- |
- |
- |
- |
(31) |
- |
(31) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive (loss)/income for the period |
|
|
- |
- |
- |
- |
- |
- |
(31) |
(765) |
(796) |
|
|
|
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
|
Balance at 30 June 2025 |
|
|
11,057 |
- |
- |
- |
46 |
1,288 |
5,437 |
(16,563) |
1,264 |
|
|
|
|
|
|
|
|
|
|
|
CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unaudited |
|
Audited |
|
Unaudited |
|
Audited |
|
|
|
30/06/2026 |
|
31/12/2025 |
|
30/06/2026 |
|
31/12/2025 |
|
|
|
€'000 |
|
€'000 |
|
US $'000 |
|
US $'000 |
|
Assets |
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
|
Trade and other receivables |
|
108 |
|
70 |
|
123 |
|
83 |
|
Cash and cash equivalents |
|
1,310 |
|
2,005 |
|
1,494 |
|
2,359 |
|
|
|
1,418 |
|
2,075 |
|
1,617 |
|
2,442 |
|
|
|
|
|
|
|
|
|
|
|
Assets held for sale |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets |
|
1,418 |
|
2,075 |
|
1,617 |
|
2,442 |
|
|
|
|
|
|
|
|
|
|
|
Equity and liabilities |
|
|
|
|
|
|
|
|
|
Equity |
|
|
|
|
|
|
|
|
|
Ordinary shares |
|
11,751 |
|
11,057 |
|
16,409 |
|
15,586 |
|
Share premium |
|
2,155 |
|
- |
|
2,503 |
|
- |
|
Capital contribution |
|
13,550 |
|
13,550 |
|
14,725 |
|
14,725 |
|
Other reserves |
|
1,288 |
|
1,288 |
|
1,774 |
|
1,774 |
|
Foreign currency translation reserve |
|
4,317 |
|
5,591 |
|
1,348 |
|
2,880 |
|
Share based payment reserve |
|
42 |
|
46 |
|
47 |
|
52 |
|
Retained earnings |
|
(31,909) |
|
(30,752) |
|
(35,445) |
|
(34,099) |
|
|
|
1,194 |
|
780 |
|
1,362 |
|
918 |
|
Non controlling interest |
|
- |
|
- |
|
- |
|
- |
|
|
|
1,194 |
|
780 |
|
1,362 |
|
918 |
|
|
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
|
Trade and other payables |
|
224 |
|
1,295 |
|
254 |
|
1,524 |
|
Provisions |
|
- |
|
- |
|
- |
|
- |
|
|
|
224 |
|
1,295 |
|
254 |
|
1,524 |
|
|
|
|
|
|
|
|
|
|
|
Liabilities included in the disposal group classified as held for sale |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total equity and liabilities |
|
1,418 |
|
2,075 |
|
1,617 |
|
2,442 |
|
|
|
|
|
|
|
|
|
|
|
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unaudited |
|
Unaudited |
|
Unaudited |
|
Unaudited |
|
|
|
30/06/2026 |
|
30/06/2025 |
|
30/06/2026 |
|
30/06/2025 |
|
|
|
€'000 |
|
€'000 |
|
US $'000 |
|
US $'000 |
|
|
|
|
|
|
|
|
|
|
|
Cash flows from operating activities |
|
|
|
|
|
|
|
|
|
Loss for the period before tax |
|
(1,203) |
|
(765) |
|
(1,397) |
|
(879) |
|
Depreciation and amortisation |
|
- |
|
- |
|
- |
|
- |
|
Share options expense |
|
8 |
|
- |
|
9 |
|
0 |
|
Finance income |
|
- |
|
3 |
|
- |
|
3 |
|
Decrease/(Increase) in inventories |
|
- |
|
- |
|
- |
|
- |
|
Decrease/(Increase) in trade and other receivables |
|
(37) |
|
19 |
|
(40) |
|
14 |
|
(Decrease)/increase in trade and other payables |
|
(1,072) |
|
(180) |
|
(1,269) |
|
(168) |
|
Net decrease in assets & liabilities included in the disposal group |
|
- |
|
(24) |
|
- |
|
(5) |
|
Goodwill impairment |
|
- |
|
- |
|
- |
|
- |
|
Net cash used in operating activities |
|
(2,304) |
|
(947) |
|
(2,696) |
|
(1,037) |
|
|
|
|
|
|
|
|
|
|
|
Cash flow from financing activities |
|
|
|
|
|
|
|
|
|
Proceeds from fundraise share issue |
|
1,331 |
|
- |
|
1,579 |
|
- |
|
Loan repayment |
|
- |
|
- |
|
- |
|
- |
|
Finance costs |
|
(4) |
|
(3) |
|
(5) |
|
(3) |
|
Net cash generated from financing activities |
|
1,327 |
|
(3) |
|
1,574 |
|
(3) |
|
Cash flows from investing activities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additions of research and development costs internally developed |
|
- |
|
- |
|
- |
|
- |
|
Revaluation of Intangible assets |
|
- |
|
- |
|
- |
|
- |
|
Additions to property, plant and equipment |
|
- |
|
- |
|
- |
|
- |
|
Net cash generated from investing activities |
|
0 |
|
0 |
|
0 |
|
0 |
|
|
|
|
|
|
|
|
|
|
|
Effects of foreign exchange |
|
282 |
|
(28) |
|
257 |
|
213 |
|
|
|
|
|
|
|
|
|
|
|
Net decrease in cash and cash equivalents |
|
(695) |
|
(977) |
|
(865) |
|
(826) |
|
Cash and cash equivalents at the beginning of period |
|
2,005 |
|
2,506 |
|
2,359 |
|
2,610 |
|
Cash and cash equivalents at the end of the period |
|
1,310 |
|
1,529 |
|
1,494 |
|
1,784 |
|
|
|
|
|
|
|
|
|
|
|
Cash and Cash equivalents included in the disposal group |
|
- |
|
3 |
|
- |
|
4 |
|
|
|
|
|
|
|
|
|
|
|
Cash and Cash Equivalents for Continuing operations |
|
1,310 |
|
1,526 |
|
1,494 |
|
1,788 |
Talisman Metals PLC
Interim results for the six months ended 30 June 2026
The interim consolidated financial statements for the six months ended 30 June 2026 are presented in €'000, which is the functional currency of the Group. The US$'000 are shown for information purposes only. The financial statements have been prepared in accordance with IAS 34 'Interim Financial Reporting' as issued by the International Accounting Standards Board as adopted by European Union.
The interim consolidated financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group's annual financial statements for the financial year ended 31 December 2025.
The accounting policies adopted in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the Group's annual financial statements for the financial year ended 31 December 2025.
Other pronouncements - Some accounting pronouncements which have become effective from 1 January 2026 and have therefore been adopted do not have a significant impact on the Group’s financial results or position.
The directors have reviewed the current state of the group’s finances, taking into account resources currently available. The Company is also reliant on future fundraises, most likely in the form of equity placings and given its history for being able to attract fresh capital, the directors are satisfied that sufficient funding will be available to the Group to enable it to trade for the foreseeable future. On this basis the directors consider that it is appropriate to prepare the financial statements on the going concern basis. The directors consider that in preparing the financial statements they have taken into account all information that could reasonably be expected to be available. The financial statements do not include any adjustments that would result if the directors' plans were not successful.
When preparing the interim financial statements, management undertakes a number of judgements, estimates and assumptions about recognition and measurement of assets, liabilities, income and expenses. The actual results may differ from judgements, estimates and assumptions made by management, and will seldom equal the estimated results. The judgements, estimates and assumptions applied in the Interim Financial Statements, including the key sources of estimation uncertainty, were the same as those applied in the Group's last annual financial statements for the financial year ended 31 December 2025.
Information regarding the Group’s operating segments is set out below in accordance with IFRS 8 Operating Segments. IFRS 8 requires operating segments to be identified on the basis of internal reports that are regularly reviewed by the Group’s chief operating decision maker and used to allocate resources to the segments and to assess their performance.
At 30 June 2026, the Group operates as a single operating segment. Management, working with the directors of the company, review the financial performance and allocates resources on a consolidated basis in line with one overarching strategic plan. The Group’s activities are integrated and relate solely to the exploration and evaluation of mineral resources. The bio pharmaceutical and investment segments are shown for comparative for the prior year.
|
|
Continuing Operations |
|
|
|
|
|
|
|
|
Period ended 30 June 2026 |
|
|
Bio-pharmaceutical |
Investment |
Mining |
Total |
|
|
|
|
|
€'000 |
€'000 |
€'000 |
€'000 |
|
|
|
|
|
|
|
|
|
|
|
Administration expenses |
|
|
|
|
(856) |
(856) |
|
|
Share based payments costs |
|
|
|
|
(8) |
(8) |
|
|
Other gains/(losses) |
|
|
|
|
(335) |
(335) |
|
|
Operating loss |
|
|
|
|
(1,199) |
(1,199) |
|
|
|
|
|
|
|
|
|
|
|
Finance costs |
|
|
|
|
(4) |
(4) |
|
|
Finance income |
|
|
|
|
- |
- |
|
|
|
|
|
|
|
|
|
|
|
Loss before tax |
|
|
|
|
(1,203) |
(1,203) |
|
|
|
|
|
|
|
|
|
|
|
Income Tax |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss after tax |
|
|
|
|
(1,203) |
(1,203) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Period ended 30 June 2025 |
|
|
Bio-pharmaceutical |
Investment |
Administrative |
Total |
|
|
|
|
|
€'000 |
€'000 |
€'000 |
€'000 |
|
|
|
|
|
|
|
|
|
|
|
Administration expenses |
|
|
- |
(20) |
(632) |
(652) |
|
|
Other gains/(losses) |
|
|
- |
436 |
(532) |
(96) |
|
|
Operating loss |
|
|
0 |
416 |
(1,164) |
(748) |
|
|
|
|
|
|
|
|
|
|
|
Finance costs |
|
|
- |
- |
(3) |
(3) |
|
|
Finance income |
|
|
- |
- |
- |
- |
|
|
|
|
|
|
|
|
|
|
|
Loss before tax |
|
|
- |
416 |
(1,167) |
(750) |
|
|
|
|
|
|
|
|
|
|
|
Income Tax |
|
|
- |
- |
- |
- |
|
|
|
|
|
|
|
|
|
|
|
Loss after tax |
|
|
- |
416 |
(1,167) |
(750) |
|
|
|
|
|
|
|
|
|
|
|
Segment assets |
|
|
- |
- |
1,561 |
1,562 |
|
|
Segment liabilities |
|
|
- |
- |
(186) |
(186) |
|
|
Net assets |
|
|
- |
- |
1,375 |
1,376 |
The Group monitors relevant aspects of financial instrument risk on an ongoing basis. Financial instrument risks primarily relates to foreign exchange risk, credit risk, liquidity risk and market risk as reported in the 31 December 2025 annual report.
|
|
|
Unaudited |
Audited |
Unaudited |
Audited |
|
|
|
|
|
|
|
|
|
|
30/06/2026 |
31/12/2025 |
30/06/2026 |
31/12/2025 |
|
|
|
€'000 |
€'000 |
US$'000 |
US$'000 |
|
|
|
|
|
|
|
|
|
Financial assets not measured at fair value |
|
|
| |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
1,310 |
2,005 |
1,494 |
2,359 |
|
|
Other debtors |
108 |
70 |
123 |
83 |
|
|
|
|
|
|
|
|
|
|
1,418 |
2,075 |
1,617 |
2,442 |
|
|
|
|
|
|
|
|
|
Financial liabilities not measured at fair value |
|
|
| |
|
|
Trade and other payables |
224 |
1,295 |
254 |
1524 |
|
|
|
|
|
|
|
|
|
|
224 |
1,295 |
254 |
1,524 |
The carrying amount of the financial assets and liabilities is considered a reasonable approximation of fair value:
On 28 January 2026, T Metals completed the acquisition of Tadeen International Limited, constituting a reverse takeover under AIM Rules. Following completion, the Enlarged Share Capital of 64,174,918 ordinary shares of €0.02 each was admitted to trading on AIM at an issue price of 7.7 pence per share.
As part of the transaction, Talisman issued shares in itself recognised in the accounts at €1.7m in share capital and share premium. The Tadeen Group did not meet the business test under IFRS 3, among other things it is currently not capable of producing outputs in the future. For this reason the acquisition was accounted for under IFRS 9 recognising a financial asset in the single entity accounts of T Metals.
As part of the transaction the following were also issued:
• New Ordinary Shares pursuant to a placing of £350,000; and
• Subscription Shares raising £805,000.
Total gross proceeds from the fundraising amounted to £1,155,000, resulting in total cash resources of approximately £2.255 million on Admission. Following Admission, the Company changed its name to Talisman Metals PLC. The acquisition has been accounted for as a reverse takeover, with Tadeen International Limited treated as the accounting acquirer.
The company made no distributions during the period.
'Subsequent to reporting period end, on 20 August 2026 the Company completed a share placement of £501,800 in gross proceeds through the issue of 7,168,570 new ordinary shares of EUR0.02 par value each.
The interim report was approved by the Board of Directors on 30 September 2026 and is included on the Company's website, www.talismanmetalsplc.com